Status and phase
Conditions
Treatments
About
The purposed of this study is to determine whether an infusion with specialized 'modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker will reduce the risk of relapse after transplant.
Sex
Ages
Volunteers
Inclusion criteria
The following criteria must be met prior to the allogenic transplantation:
ALL in second remission or greater (≥ CR2)
CLL
B-NHL
Patient's age is ≥ 18 and ≤ 60.
KPS ≥ 70%
Patients must have CD19 expression (by any detection method) demonstrated on their malignant cells at the time of enrollment on the protocol.
Patients relapsed after prior CD19 CAR T cell or blinatumomab are eligible for enrollment as long as CD19 expression is still prese on the malignant cells.
Patients who have a matched related donor willing to donate HSC for allograft and PBMC for CAR T cell generation
Patients must have adequate organ function measured by:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
0 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal